Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

NowPatient vs T2D.com

An in-depth comparison of two leading GLP-1 Providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

7.1

NowPatient

Best for early adopters who want Foundayo via a one-stop telehealth platform

Starting at $199/mo

FoundayoTelehealthBrand Name
Visit NowPatient
6.1

T2D.com

Best for diabetic GLP-1 access

Starting at $999/mo

CompoundedSemaglutideTirzepatidePrescriber Included
Visit T2D.com

Side-by-Side Comparison

FeatureNowPatientT2D.com
Overall Score7.1/106.1/10
Starting Price$199/mo$999/mo
Customer Rating
Features3 features7 features
States Available511
Compounded✓ Yes
Brand Name✓ Yes
FSA/HSA Accepted
FDA WarningsNoneNone

Pros & Cons

NowPatient

Pros

  • Confirmed early Foundayo channel (April 2026 rollout)
  • Daily oral pill — no needles, no refrigeration
  • Telehealth consultation included

Cons

  • Pricing tier not yet publicly verified — confirm directly with the provider
  • State-by-state availability still being phased in
  • Lower mean weight loss vs injectable GLP-1s (~11.1% vs 14.9% Wegovy and 20.9% Zepbound at labeled max)

T2D.com

Pros

  • Built specifically for type 2 diabetic and pre-diabetic patients
  • Integrated service — prescriber, pharmacy, and delivery handled in one flow
  • Offers both compounded semaglutide and compounded tirzepatide
  • Temperature-controlled home delivery via UPS or FedEx
  • Ongoing prescriber monitoring and support included

Cons

  • No pricing published on the public website — must register to see costs
  • No states list published on the site
  • Newer brand with limited independent reviews
  • Compounded only — no brand-name Ozempic, Wegovy, or Mounjaro

Our Verdict

Winner: NowPatientScore: 7.1/10

NowPatient edges out T2D.com with a higher overall score of 7.1/10 and is particularly strong for early adopters who want Foundayo via a one-stop telehealth platform. T2D.com remains a solid alternative, especially if you're looking for diabetic GLP-1 access.

Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.